Alexion’s Son of Soliris Aims To Takes Dosing Right Down
Executive Summary
Alexion is setting its sights on eight-weekly dosing for its follow-up candidate to its blockbuster Soliris, testing this schedule in its new Phase III trial in patients with paroxysmal nocturnal hemoglobinuria (PNH), based on new Phase I/II data just presented at the ASH meeting in San Diego.
You may also be interested in...
While You Were Out: News In Brief
Updates from the holiday season include a Phase III failure for Pfizer's MRSA vaccine, AbbVie's submission of upadacitinib for rheumatoid arthritis and several year-end US approvals and FDA actions.
No One-Trick Pony: Alexion’s Evolution Into A Multi-Asset Drug Company
Alexion has been recognized mainly as the marketer of Soliris since 2007, but in just eight weeks the rare disease specialist added two new drugs to its commercial portfolio. Management also laid out an impressive early- to mid-stage pipeline during its first-ever investor day, suggesting the company is well positioned for long-term growth.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.